A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.

This is a single-centre, single-arm, open-label, early clinical study to evaluate the safety, tolerability and preliminary efficacy of donor NK cells injection combined with low-dose interleukin-2 in the treatment of acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Trial Details

NCT ID
NCT06641648
Phase
PHASE1
Sponsor
Peking University First Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • NK cell
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Age ≥ 18 years old,;
  • Expected survival period ≥ 3 months;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2;
  • The diagnosis of AML who received allo-HSCT, and met the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →